A Randomized, Open-label, Parallel, Phase I/II Single-Dose Administration Trial of TLC599 in Subjects With Osteoarthritis of the Knee

Trial Profile

A Randomized, Open-label, Parallel, Phase I/II Single-Dose Administration Trial of TLC599 in Subjects With Osteoarthritis of the Knee

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Jan 2017

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions
  • Sponsors Taiwan Liposome Company
  • Most Recent Events

    • 03 Jan 2017 According to a Taiwan Liposome Company media release, the observation period has lengthened to 24 weeks compared to the 12 week duration in this trial to determine the maximum duration of efficacy.
    • 16 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 18 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top